NO20060200L - Farmasoytisk formulering for prevensjons- og hormonerstatningsterapier - Google Patents

Farmasoytisk formulering for prevensjons- og hormonerstatningsterapier

Info

Publication number
NO20060200L
NO20060200L NO20060200A NO20060200A NO20060200L NO 20060200 L NO20060200 L NO 20060200L NO 20060200 A NO20060200 A NO 20060200A NO 20060200 A NO20060200 A NO 20060200A NO 20060200 L NO20060200 L NO 20060200L
Authority
NO
Norway
Prior art keywords
pharmaceutical formulation
hormone replacement
contraceptive
replacement therapies
estradiol
Prior art date
Application number
NO20060200A
Other languages
English (en)
Other versions
NO341540B1 (no
Inventor
Juan Angeles Uribe
John Claude Savoir
Original Assignee
John Claude Savoir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060200(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by John Claude Savoir filed Critical John Claude Savoir
Publication of NO20060200L publication Critical patent/NO20060200L/no
Publication of NO341540B1 publication Critical patent/NO341540B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer langsom fiigivelse estradiol-progesteronformuleringer som kan brukes enten i prevensjons- eller hormonerstatningsterapier. Formuleringene omfatter formede partikler av estiadiol som er i hemikrystallinsk form som utviser spesielt lave oppløsningsrater. De formede partiklene omfatter estiadiol sammensatt i et 1:1 molforhold med kolesterol, og administieres i kombinasjon med progesteron. De langsomme fiigivelsesformuleringene av den foreliggende oppfinnelsen frembyr de tosidige fordelene av en lavdoserings-esfradiolformulering med et lavfrekvens- adminisfreringsregime. Formuleringene kan adminisfreres parenteralt en gang i måneden eller sjeldnere.
NO20060200A 2003-06-13 2006-01-13 Estradiolprogesteron-formulering med langsom frigivelse for prevensjons- og hormonerstatningsterapier NO341540B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47793903P 2003-06-13 2003-06-13
PCT/IB2004/001930 WO2004110408A2 (en) 2003-06-13 2004-06-10 Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol

Publications (2)

Publication Number Publication Date
NO20060200L true NO20060200L (no) 2006-01-13
NO341540B1 NO341540B1 (no) 2017-12-04

Family

ID=33551788

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060200A NO341540B1 (no) 2003-06-13 2006-01-13 Estradiolprogesteron-formulering med langsom frigivelse for prevensjons- og hormonerstatningsterapier

Country Status (23)

Country Link
US (2) US7589082B2 (no)
EP (3) EP1820494B1 (no)
JP (2) JP4956185B2 (no)
CN (2) CN100594907C (no)
AT (1) ATE454885T1 (no)
AU (1) AU2004246870B2 (no)
BR (1) BRPI0411335A (no)
CA (2) CA2528545C (no)
CY (1) CY1109967T1 (no)
DE (1) DE602004025156D1 (no)
DK (3) DK1820494T3 (no)
EA (3) EA026709B1 (no)
ES (3) ES2340422T3 (no)
HU (1) HUE025147T2 (no)
IL (2) IL172466A (no)
MX (1) MX2008014654A (no)
NO (1) NO341540B1 (no)
OA (1) OA13307A (no)
PL (3) PL1663161T3 (no)
PT (3) PT1820494E (no)
SI (3) SI1820494T1 (no)
TW (1) TWI336623B (no)
WO (1) WO2004110408A2 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340422T3 (es) 2003-06-13 2010-06-02 Skendi Finance, Ltd. Microparticulas constituidas por estradiol y colesterol.
JP2011516606A (ja) * 2008-04-14 2011-05-26 ポジ ビジョナリー ソリューションズ エルエルピー 様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2012129305A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination therapy
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018069877A2 (pt) * 2016-04-01 2019-02-05 Therapeuticsmd Inc composição farmacêutica de hormônio esteróide
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3272732B1 (de) 2016-07-19 2019-09-18 Evonik Degussa GmbH Verfahren zur alkoxycarbonylierung ethylenisch ungesättigter verbindungen mit monophosphinliganden
KR102954589B1 (ko) * 2018-11-29 2026-04-20 인시그나 인크. 불임제로서의 에스트라디올 벤조에이트
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP3954364A1 (en) * 2020-08-14 2022-02-16 Chemo Research, S.L. New modified release oral contraceptive composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
GB1367608A (en) * 1973-03-09 1974-09-18 Biolog Concepts Inc Oral pharmaceutical dosage form
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US4180560A (en) * 1976-10-26 1979-12-25 Syntex Corporation Inert core implant pellet
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
US5023092A (en) 1988-06-16 1991-06-11 Ici Americas Inc. Mannitol having gamma sorbitol polymorph
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
FR2747042B1 (fr) * 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
EP0888790A1 (en) 1997-07-04 1999-01-07 PowderJect Research Limited Drug particle delivery device
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
DK1361881T3 (da) * 2000-12-14 2006-02-20 Ortho Mcneil Pharm Inc Steroide hormonprodukter og fremgangsmåder til fremstilling heraf
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
ES2340422T3 (es) 2003-06-13 2010-06-02 Skendi Finance, Ltd. Microparticulas constituidas por estradiol y colesterol.

Also Published As

Publication number Publication date
EA012783B1 (ru) 2009-12-30
HUE025147T2 (hu) 2016-03-29
HK1097735A1 (zh) 2007-07-06
CN101816662B (zh) 2015-01-28
DK1663161T3 (en) 2015-04-27
SI1844765T1 (sl) 2015-05-29
NO341540B1 (no) 2017-12-04
EA018356B1 (ru) 2013-07-30
US7589082B2 (en) 2009-09-15
EP1820494B1 (en) 2010-01-13
EA201201221A1 (ru) 2014-02-28
IL210851A (en) 2016-05-31
EA200900451A1 (ru) 2009-12-30
AU2004246870A1 (en) 2004-12-23
CY1109967T1 (el) 2014-09-10
PT1844765E (pt) 2015-05-20
CA2849228C (en) 2016-09-20
JP4956185B2 (ja) 2012-06-20
TW200514560A (en) 2005-05-01
IL172466A (en) 2011-11-30
EP1663161B1 (en) 2015-01-14
CA2528545C (en) 2014-08-12
JP2006527263A (ja) 2006-11-30
DE602004025156D1 (de) 2010-03-04
ES2537551T3 (es) 2015-06-09
DK1844765T3 (en) 2015-04-27
HK1147426A1 (en) 2011-08-12
CA2849228A1 (en) 2004-12-23
OA13307A (en) 2007-04-13
TWI336623B (en) 2011-02-01
EA200600029A1 (ru) 2006-08-25
CN1835737A (zh) 2006-09-20
PL1820494T3 (pl) 2010-07-30
PL1663161T3 (pl) 2015-08-31
PL1844765T3 (pl) 2015-06-30
SI1820494T1 (sl) 2010-08-31
BRPI0411335A (pt) 2006-07-25
HK1109586A1 (en) 2008-06-13
US20090081303A1 (en) 2009-03-26
CN101816662A (zh) 2010-09-01
EP1820494A3 (en) 2007-09-19
ES2340422T3 (es) 2010-06-02
CN100594907C (zh) 2010-03-24
CA2528545A1 (en) 2004-12-23
SI1663161T1 (sl) 2015-05-29
EP1820494A2 (en) 2007-08-22
HK1106717A1 (en) 2008-03-20
IL210851A0 (en) 2011-04-28
AU2004246870B2 (en) 2009-07-23
ATE454885T1 (de) 2010-01-15
WO2004110408A3 (en) 2005-04-14
EA026709B1 (ru) 2017-05-31
IL172466A0 (en) 2006-04-10
DK1820494T3 (da) 2010-05-25
PT1663161E (pt) 2015-05-13
WO2004110408A2 (en) 2004-12-23
EP1844765A1 (en) 2007-10-17
EP1844765B1 (en) 2015-01-21
MX2008014654A (es) 2009-03-09
US8163722B2 (en) 2012-04-24
JP2011157386A (ja) 2011-08-18
PT1820494E (pt) 2010-04-14
ES2537563T3 (es) 2015-06-09
EP1663161A2 (en) 2006-06-07
US20050025827A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
IL210851A0 (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
ID29181A (id) Kombinasi formoterol dan garam tiotropium
JP2002523375A5 (no)
WO2002045703A3 (en) Mixtures or organic compounds for the treatmentof airway diseases
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
BR0015284A (pt) Formulações de hidrocodona de liberação controlada
BRPI0412493A (pt) métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
SE9704833D0 (sv) New formulation
EA200301022A1 (ru) Гормональная заместительная терапия
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
JP2007504268A5 (no)
JP2002540148A5 (no)
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
BR0312140A (pt) Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazes
HUP0302984A2 (hu) Buprenorphin felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
CR8010A (es) Regimenes de contraceptivos transdermicos extendidos
CY1116203T1 (el) Σκευασμα οιστραδιολης-προγεστερονης βραδειας αποδεσμευσης
AR033260A1 (es) Nueva composicion hormonal y su utilizacion
BR122014030158B8 (pt) formulação farmacêutica

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees